CytaCoat
Graeme Brookes has extensive experience in the medical technology industry, holding various executive and leadership roles. Graeme served as the Chief Executive Officer of CytaCoat, a company developing anti-microbial coatings for medical devices. Prior to that, they were the CEO of Reapplix, specializing in biological treatments for diabetic foot ulcers. Brookes also held positions at Stanmore Implants, Acrobot, MDTi/remedi UK Ltd, and Advanced Medical Solutions Group PLC, where they were involved in product development, sales, marketing, and business development. Graeme'searlier experience includes roles at Johnson & Johnson Orthopaedics and Amersham International plc.
Graeme Brookes obtained a BSc in Chemistry from the University of Nottingham from 1980 to 1983.
This person is not in any offices
CytaCoat
1 followers
CytaCoat is developing a new technology of antibacterial coating for medical devices. CytaCoat AB is a private Swedish company located in the Karolinska Institutet Science Park AB in Solna (Stockholm area). The company was founded by a group of researchers from the Karolinska Institute, one of the foremost medical universities in the world, and theRoyal Institute of Technology (KTH). It was a special purpose vehicle started with a goal to develop a new technology of antibacterial coating for medical devices. It was based on a discovery that their proprietary polymer surface exhibits a clear effect on several of the most problematic pathogenic bacteria that pose problems in healthcare today. Since then, the company has been focused on transforming this innovation into a fully viable commercial product and make it available through licenses.CytaCoat has a fully equipped laboratory in the Karolinska Institutet Science Park, where both microbiology evaluation, optimisation of the CytaCoat technology and a pilot plant production can be performed. The company has also established contacts with clinical collaborators at Karolinska University Hospital Neonatal Unit and the Division of Clinical Microbiology. CytaCoat has also been cooperating with experienced consultants in regulatory, clinical research organisations, patent experts and providers of specialist analyses.